Cipla launches Hepatitis B vaccine in India
Avalokita Pandey / 17 Feb 2017
Cipla, a global pharmaceutical & biotechnology company, has announced that it has launched adult Hepatitis B vaccine in India, under a co-exclusive agreement with the Serum Institute of India Private Limited (SII).
Cipla, a global pharmaceutical & biotechnology company, has announced that it has launched adult Hepatitis B vaccine in India, under a co-exclusive agreement with the Serum Institute of India Private Limited (SII). Cipla will market the vaccine for adults while SII will market it for adults and children.
The stock of the company is trading with the gains at Rs 593.65, up 9.05 or at 1.55 per cent. In the last one year, the stock has given a return of 15 per cent.
SII is the world's second largest vaccine manufacturer as it manufacture and supply doses to more than 140 countries.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.